Study of BC008-1A for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This trial tests a new drug called BC008-1A for people with advanced esophageal cancer or non-small cell lung cancer that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced esophageal cancer or a type of non-small cell lung cancer (squamous or adenocarcinoma) that has not responded to standard treatment.
- You are 18 years or older and have an expected survival of at least 12 weeks (about 3 months).
- You have at least one tumor that can be measured on a CT or MRI scan.
- You are physically active enough to do daily activities (ECOG score 0 or 1).
- Your blood counts, liver, and kidney functions are within certain limits (your doctor will check this).
- You have not been treated with any anti-TIGIT drug before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for advanced solid tumors, specifically esophageal cancer. It may help people whose cancer has not responded to other treatments.
This trial tests a new drug called BL-B01D1 combined with an immune therapy (tislelizumab) and sometimes chemotherapy against standard chemotherapy for esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this new combination works better and is safer than current treatment.
This trial tests a new drug (ES102) combined with an immunotherapy (Toripalimab) for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help those whose tumors have high PD-L1 levels.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
This trial tests a new drug called MC002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to find the right dose and see if the drug is safe and effective.
Hear when a new Advanced Esophageal Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.